Stocks Health care VOR
NASDAQ · Health careVor Biopharma Inc. (VOR)
In fiscal 2025 capital spending exceeded operating cash flow by $143.7M. At September 30, 2026 it held $79M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 30, 2026.
Key facts about Vor Biopharma Inc.
- Net worth
- Vor Biopharma Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of -$137.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $142.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 30, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Vor Biopharma Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Vor Biopharma Inc. does
Vor Biopharma Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VOR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$696M | -$70.50 | -$143.7M |
| 2024 | n/a | -$116.9M | -$34.03 | -$99.9M |
| 2023 | n/a | -$117.9M | -$35.03 | -$101.4M |
| 2022 | n/a | -$92.1M | -$46.64 | -$93.6M |
| 2021 | n/a | -$68.9M | -$42.04 | -$73M |
| 2021 | n/a | -$43.3M | -$4,615.47 | -$40.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Vor Biopharma Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- October 30, 2026
- September 4, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Vor Biopharma Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Sokolove Jeremy BrettChief Medical Officer | Shares withheld for tax | 1,917 | $36.9K |
| October 2, 2026 | Ra Capital Management, L.P.10% owner | Exercised optionsindirect | 500 | $6.4K |
| August 24, 2026 | Ra Capital Management, L.P.10% owner | Exercised optionsindirect | 1,500 | $5.6K |
| July 16, 2026 | Ra Capital Management, L.P.10% owner | Exercised optionsindirect | 2,100,000 | $4.2K |
| July 16, 2026 | Ra Capital Management, L.P.10% owner | Soldindirect | 213 | $4.2K |
| April 22, 2026 | Ra Capital Management, L.P.Director, 10% owner | Soldindirect | 165,150 | $2.6M |
| April 20, 2026 | Ra Capital Management, L.P.Director, 10% owner | Soldindirect | 171,963 | $2.7M |
| April 17, 2026 | Ra Capital Management, L.P.Director, 10% owner | Soldindirect | 458,411 | $7.5M |
Who owns VOR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 19.9% | July 21, 2026 |
| Reprogrammed Interchange LLC13D, may seek influence with 1 related filers | 17.6% | October 17, 2025 |
| Fmr LLC13G, passive with 1 related filers | 12% | August 7, 2026 |
| Chen Yu13G, passive with 4 related filers | 10.5% | April 1, 2026 |
| ForGrowth III PA B.V.13D, may seek influence with 2 related filers | 9.99% | December 23, 2025 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 9.9% | August 14, 2026 |
| Verve Capital Limited13G, passive | 6.3% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 102 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| TCG Crossover Management, LLC | 5,673,078 | 0 |
| Fmr LLC | 4,932,149 | +3,392,479 |
| Fcpm III Services B.V. | 4,117,354 | 0 |
| BlackRock, Inc. | 3,468,107 | +2,673,348 |
| Venrock Adviser, LLC | 3,041,719 | 0 |
| State Street Corp | 2,616,336 | +1,497,878 |
| Frazier Life Sciences Management, L.P. | 2,543,939 | 0 |
| RA Capital Management, L.P. | 2,402,095 | -3,002,903 |
| Vanguard Capital Management LLC | 2,084,328 | +651,048 |
| Caligan Partners LP | 1,925,066 | 0 |
| Paradigm Biocapital Advisors LP | 1,750,000 | 0 |
| Great Point Partners LLC | 1,700,000 | -50,000 |
| Nantahala Capital Management, LLC | 1,690,000 | new |
| Geode Capital Management, LLC | 1,062,469 | +719,896 |
| NEXTBio Capital Management LP | 889,164 | -110,803 |
| ADAR1 Capital Management, LLC | 680,626 | new |
| Logos Global Management LP | 650,000 | -100,000 |
| Rosalind Advisors, Inc. | 648,600 | -51,400 |
| Nan Fung Trinity (HK) Ltd | 646,550 | new |
| Braidwell LP | 573,104 | +106,330 |
Insiders
2 insiders reported holding 26,483 shares in total, about $529.1K at the last price.
| Holder | Shares |
|---|---|
| Sokolove Jeremy BrettChief Medical Officer | 25,983 |
| Ra Capital Management, L.P.10% owner | 500500 held indirectly |
Questions about VOR
What does Vor Biopharma Inc. do?
Vor Biopharma Inc. is a company in the Health care sector, listed on NASDAQ as VOR. Its shares trade on NASDAQ under the ticker VOR.
What is Vor Biopharma Inc.'s net worth?
Vor Biopharma Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of -$137.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vor Biopharma Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $1.4B.
When did Vor Biopharma Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 30, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Vor Biopharma Inc.'s next earnings report?
Vor Biopharma Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VOR with
Follow VOR
Get an email when Vor Biopharma Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vor Biopharma Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.